Preclinical studies have shown that inhibition of XPO-1 can lead to p53 nuclear accumulation and blockade of the NF-κB signaling pathway, both of which are therapeutic targets in MDS (30, 31). The gene discussed is NFKB1; the disease is myelodysplastic syndrome.